Actively Recruiting
Investigating Interferon and Complement Roles in Secondary Thrombotic Microangiopathy After Transplantation
Led by Sofie Dhaese · Updated on 2026-10-28
40
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the role of interferon IFN and complement activation in the development of secondary thrombotic microangiopathy TMA, particularly transplantation-associated TMA TA-TMA. Viral infections, such as cytomegalovirus CMV, increase IFN levels, which may contribute to TMA by disrupting the vascular endothelial growth factor VEGF pathway in the kidney. This study aims to clarify whether IFN alongside complement dysregulation drives endothelial damage leading to TMA. The study involves collecting blood and urine samples from different patient groups including those with TMA after hematopoietic stem cell transplantation HSCT or solid organ transplantation SOT, patients with viral infections without TMA, and patients with drug-induced TMA. Samples are taken at baseline and monitored up to 52 weeks to measure interferon signatures, VEGF-A levels, and complement activity. Participants will provide biological samples at specified times to support analyses of IFN, VEGF, and complement markers. The research team will assess associations between these markers and the presence or development of TMA. Study participation includes monitoring these biomarkers over about one year, with no investigational drug administration. This observational approach helps understand the disease mechanisms and potential risk factors in patients after transplantation.
CONDITIONS
Brief Title
The Role of interferOn and Complement in SecondAry thRombotic micrioangiOpathy
Research Team
S
Sofie A Dhaese, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here